Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: A nested case-control study

American Journal of Kidney Diseases

Volumn 60, Issue 1, 2012, Pages 82-89

  Lafrance, Jean Philippe ^a,b   Miller, Donald R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adverse effects; Anti inflammatory agents; case control studies; cyclooxygenase 2 inhibitors; hyperkalemia; nonsteroidal

Indexed keywords

CELECOXIB; CONTRAST MEDIUM; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; ROFECOXIB; SALSALATE;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HEALTH CARE SYSTEM; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POTASSIUM BLOOD LEVEL; RACE; RISK FACTOR; UNITED STATES; VETERAN;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; HYPERKALEMIA; INTERNATIONAL CLASSIFICATION OF DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84862616777     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.02.328     Document Type: Article

References (32)

1. Alfonzo AVM, Isles C, Geddes C, Deighan C. Potassium disorders - clinical spectrum and emergency management. Resuscitation. 2006;70(1):10-25.
2. Shingarev R, Allon M. A physiologic-based approach to the treatment of acute hyperkalemia. Am J Kidney Dis. 2010;56(3):578-584.
3. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol. 2006;1(2):236-245.
4. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619-1632.
5. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-889.
6. Lafrance JP, Miller DR. Selective and non-selective nonsteroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf. 2009;18(10):923-931.
7. Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2010;19(11):1194-1198.
8. Boyko EJ, Koepsell TD, Gaziano JM, Horner RD, Feussner JR. US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol. 2000;151(3):307-314.
9. Miller DR, Pogach L. Longitudinal approaches to evaluate health care quality and outcomes: the Veterans Health Administration Diabetes Epidemiology Cohort. J Diabetes Sci Technol. 2008;2(1):24-32.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
11. Rothman KJ. Modern Epidemiology. 1st ed. Boston, MA: Little, Brown & Co; 1986.
12. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(5):413-421.
13. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433-442.
14. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2)(suppl 1):S1-S266.
15. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:155A.
16. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006;47(1)(suppl 1):S37-S42.
17. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007;17(3):227-236.
18. Mount D, Zandi-Nejad K. Disorders of potassium balance. In: Brenner B, ed. Brenner and Rector's The Kidney. Vol 1. 8th ed. Philadelphia, PA: Saunders; 2007:547-587.
19. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31(7): 588-598.
20. Goldszer RC, Coodley EL, Rosner MJ, Simons WM, Schwartz AB. Hyperkalemia associated with indomethacin. Arch Intern Med. 1981;141(6):802-804.
21. Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38(4):700-704.
22. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002;72(1):50-61.
23. Nesher G, Zimran A, Hershko C. Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacin. Nephron. 1988;48(4):291-295.
24. Harirforoosh S, Aghazadeh-Habashi A, Jamali F. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol. 2006;33(10):917-924.
25. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-496.
26. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006;92(11):1610-1615.
27. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633-1644.
28. Raebel MA, Ross C, Cheetham C, et al. Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiol Drug Saf. 2010;19(1):19-25.
29. de Denus S, Tardif JC, White M, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J. 2006;152(4):705-712.
30. Smellie WS. Spurious hyperkalaemia. BMJ. 2007;334(7595):693-695.
31. Hoff RA, Rosenheck RA. Cross-system service use among psychiatric patients: data from the Department of Veterans Affairs. J Behav Health Serv Res. 2000;27(1):98-106.
32. Smith M, Joseph J. Pharmacy data in the VA health care system. Med Care Res Rev. 2003;60:92S-123S.